8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Jan 12, 2026·SEC
Metagenomi, Inc. Common Stock(MGX)Earnings, Financials & Key Ratios
MGX•NASDAQ
$1.32
Price updated Jul 7, 2026
AboutMetagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.Show more
- Revenue$25M-51.8%
- EBITDA-$91M-8.6%
- Net Income-$88M-12.6%
- EPS (Diluted)-2.36-12.9%
- Gross Margin78.91%-21.1%
- EBITDA Margin-359.76%-125.3%
- Operating Margin-380.85%-124.0%
- Net Margin-348.54%-133.5%
- ROE-44.67%-28.8%
MGX Price & Volume
Metagenomi, Inc. Common Stock (MGX) stock price & volume — 10-year historical chart
Loading chart...
Metagenomi Faces Severe Liquidity And Revenue Contraction
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and capital exhaustion
Key Thesis Takeaways
- Metagenomi's business model appears increasingly unsustainable as the company struggles with a 69.8% year-over-year revenue decline in 2026Q1 and the exhaustion of critical deferred revenue, which has fallen from $79.0M in 2023Q4 to $9.3M.
- The persistent reliance on high-intensity R&D spending, which reached $19.3M in the most recent quarter, continues to outpace limited licensing inflows and erode the company's asset base.
- Investors should monitor the critical depletion of cash reserves, which have plummeted to $25.3M, as the firm faces significant risks regarding its ability to fund future operations without immediate external capital.
Verdict Logic
the company's cash position has plummeted to $25.3M as of 2026Q1, signaling a critical liquidity risk that threatens the viability of its ongoing research operations.
MGX Growth Metrics
Metagenomi, Inc. Common Stock (MGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years13.59%
TTM-50.66%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-9%
Return on Capital
10 Years-26.55%
5 Years-26.55%
3 Years-31.25%
Last Year-39.56%
MGX Recent Earnings
Metagenomi, Inc. Common Stock (MGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (50%)●Beat Revenue 7/12 qtrs (70%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.61-1.7%
$0.60
Rev
$1M-78.9%
$6M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.60-3.4%
$0.58
Rev
$4M-46.6%
$7M
Q4 2025
Nov 11, 2025Metric
Actual
Est
EPS
$0.55+8.3%
$0.60
Rev
$9M+10.7%
$8M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.54+20.6%
$0.68
Rev
$9M+7.2%
$8M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.61vs $0.60-1.7% | $1Mvs $6M-78.9% |
| Q2 2026 | Mar 5, 2026 | $0.60vs $0.58-3.4% | $4Mvs $7M-46.6% |
| Q4 2025 | Nov 11, 2025 | $0.55vs $0.60+8.3% | $9Mvs $8M+10.7% |
| Q3 2025 | Aug 12, 2025 | $0.54vs $0.68+20.6% | $9Mvs $8M+7.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Metagenomi, Inc. Common Stock (MGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.32 | $49.69M | -0.56 | -51.79% | -348.54% | -44.67% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — | |
| $17.43 | $1.96B | -4.57 | 16.92% | -597.04% | -57.27% | — | |
| $3.99 | $720.66M | -2.96 | 55.28% | -4917.55% | -188.82% | — |
Compare MGX vs Peers
Metagenomi, Inc. Common Stock (MGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MGX SEC Filings & Documents
Metagenomi, Inc. Common Stock (MGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MGX Frequently Asked Questions
Metagenomi, Inc. Common Stock (MGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Metagenomi, Inc. Common Stock's revenue?
Metagenomi, Inc. Common Stock (MGX) reported $22.3M in revenue for fiscal year 2025. This represents a 9090% increase from $0.2M in 2021.
How fast is Metagenomi, Inc. Common Stock growing?
Metagenomi, Inc. Common Stock (MGX) saw revenue decline by 51.8% over the past year.
Is MGX profitable?
Metagenomi, Inc. Common Stock (MGX) reported a net loss of $85.9M for fiscal year 2025.
Dividend & Returns
What is MGX's return on equity?
Metagenomi, Inc. Common Stock (MGX) has a return on equity (ROE) of -44.7%. Negative ROE indicates the company is unprofitable.
What is Metagenomi, Inc. Common Stock's free cash flow?
Metagenomi, Inc. Common Stock (MGX) had negative free cash flow of $87.5M in fiscal year 2025, likely due to heavy capital investments.